JP2017537984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537984A5 JP2017537984A5 JP2017550464A JP2017550464A JP2017537984A5 JP 2017537984 A5 JP2017537984 A5 JP 2017537984A5 JP 2017550464 A JP2017550464 A JP 2017550464A JP 2017550464 A JP2017550464 A JP 2017550464A JP 2017537984 A5 JP2017537984 A5 JP 2017537984A5
- Authority
- JP
- Japan
- Prior art keywords
- nkt
- lpc
- activator
- hepatitis
- miltefosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 17
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 12
- 239000012190 activator Substances 0.000 claims 10
- 208000006454 hepatitis Diseases 0.000 claims 8
- 231100000283 hepatitis Toxicity 0.000 claims 8
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims 7
- OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 108700020675 O-deacetyl platelet activating factor Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- VLBPIWYTPAXCFJ-XMMPIXPASA-N lysophosphatidylcholine O-16:0/0:0 Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VLBPIWYTPAXCFJ-XMMPIXPASA-N 0.000 claims 4
- 229960003775 miltefosine Drugs 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000014997 Crohn colitis Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000001228 classical NK T cell Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 240000005125 Myrtus communis Species 0.000 claims 1
- 235000013418 Myrtus communis Nutrition 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000000037 type II NK T lymphocyte Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089690P | 2014-12-09 | 2014-12-09 | |
| US62/089,690 | 2014-12-09 | ||
| PCT/US2015/063930 WO2016094226A1 (en) | 2014-12-09 | 2015-12-04 | Prevention and treatment of inflammatory conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000288A Division JP2021059594A (ja) | 2014-12-09 | 2021-01-04 | 炎症性病態の予防および治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537984A JP2017537984A (ja) | 2017-12-21 |
| JP2017537984A5 true JP2017537984A5 (https=) | 2019-01-17 |
Family
ID=55182541
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550464A Pending JP2017537984A (ja) | 2014-12-09 | 2015-12-04 | 炎症性病態の予防および治療 |
| JP2021000288A Pending JP2021059594A (ja) | 2014-12-09 | 2021-01-04 | 炎症性病態の予防および治療 |
| JP2023000750A Active JP7573056B2 (ja) | 2014-12-09 | 2023-01-05 | 炎症性病態の予防および治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000288A Pending JP2021059594A (ja) | 2014-12-09 | 2021-01-04 | 炎症性病態の予防および治療 |
| JP2023000750A Active JP7573056B2 (ja) | 2014-12-09 | 2023-01-05 | 炎症性病態の予防および治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20160158258A1 (https=) |
| EP (1) | EP3229811B1 (https=) |
| JP (3) | JP2017537984A (https=) |
| KR (1) | KR102665487B1 (https=) |
| CN (2) | CN114712504A (https=) |
| AU (1) | AU2015360945B2 (https=) |
| BR (1) | BR112017012134A2 (https=) |
| CA (1) | CA3007970A1 (https=) |
| DK (1) | DK3229811T3 (https=) |
| ES (1) | ES2860823T3 (https=) |
| IL (1) | IL252779B (https=) |
| MX (1) | MX381284B (https=) |
| RU (1) | RU2749132C2 (https=) |
| TW (1) | TWI701032B (https=) |
| WO (1) | WO2016094226A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012272642B2 (en) | 2011-06-24 | 2017-09-07 | Gri Bio, Inc. | Prevention and treatment of inflammatory conditions |
| WO2019190986A1 (en) * | 2018-03-26 | 2019-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 3-o-sulfo-galactosylceramide analogs as activators of type ii nkt cells and uses thereof |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE59777B1 (en) * | 1985-12-04 | 1994-04-06 | Max Planck Gesellschaft | Medicaments |
| US6025388A (en) | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| US7390795B2 (en) * | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
| US20030133922A1 (en) * | 2002-01-15 | 2003-07-17 | Kasha John R. | Oral tolerance using allogeneic platelets in ITP |
| DE102004052697A1 (de) * | 2004-10-29 | 2006-05-04 | Haehner, Thomas, Dr. | Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation |
| US20110118197A1 (en) | 2005-09-29 | 2011-05-19 | Vipin Kumar Chaturvedi | Prevention of hepatic ischemic reperfusion injury by administration of sulfatides |
| DE602006019759D1 (de) | 2005-09-29 | 2011-03-03 | Torrey Pines Inst | Sulfatide zur behandlung von autoimmunkrankheiten |
| CN101355929A (zh) * | 2005-12-23 | 2009-01-28 | 哈多技术有限公司 | 治疗和预防变应性疾病的方式和方法 |
| WO2007149382A2 (en) * | 2006-06-19 | 2007-12-27 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in treating hepatitis |
| AU2012272642B2 (en) | 2011-06-24 | 2017-09-07 | Gri Bio, Inc. | Prevention and treatment of inflammatory conditions |
| US8828998B2 (en) * | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014166941A1 (en) * | 2013-04-08 | 2014-10-16 | Academisch Medisch Centrum | Miltefosin or perifosin for use in the treatment of ibd |
-
2015
- 2015-12-04 ES ES15826215T patent/ES2860823T3/es active Active
- 2015-12-04 RU RU2017123761A patent/RU2749132C2/ru active
- 2015-12-04 DK DK15826215.4T patent/DK3229811T3/da active
- 2015-12-04 JP JP2017550464A patent/JP2017537984A/ja active Pending
- 2015-12-04 CN CN202210179079.3A patent/CN114712504A/zh active Pending
- 2015-12-04 TW TW104140844A patent/TWI701032B/zh active
- 2015-12-04 MX MX2017007492A patent/MX381284B/es unknown
- 2015-12-04 CN CN201580075764.XA patent/CN107206086B/zh active Active
- 2015-12-04 BR BR112017012134-4A patent/BR112017012134A2/pt not_active Application Discontinuation
- 2015-12-04 EP EP15826215.4A patent/EP3229811B1/en active Active
- 2015-12-04 CA CA3007970A patent/CA3007970A1/en active Pending
- 2015-12-04 KR KR1020177018579A patent/KR102665487B1/ko active Active
- 2015-12-04 AU AU2015360945A patent/AU2015360945B2/en active Active
- 2015-12-04 WO PCT/US2015/063930 patent/WO2016094226A1/en not_active Ceased
- 2015-12-09 US US14/964,317 patent/US20160158258A1/en active Pending
-
2017
- 2017-06-08 IL IL252779A patent/IL252779B/en not_active IP Right Cessation
-
2021
- 2021-01-04 JP JP2021000288A patent/JP2021059594A/ja active Pending
-
2023
- 2023-01-05 JP JP2023000750A patent/JP7573056B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance | |
| JP2017537984A5 (https=) | ||
| JP2014111672A5 (https=) | ||
| JP2016503793A5 (https=) | ||
| JP2010530373A5 (https=) | ||
| JP2012092103A5 (https=) | ||
| JP2018522860A5 (https=) | ||
| JP2017535610A5 (https=) | ||
| JP2012525413A5 (https=) | ||
| JP2010534247A5 (https=) | ||
| JP2011527299A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2011227454A5 (https=) | ||
| JP2013537905A5 (https=) | ||
| JP2019516739A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2017505785A5 (https=) | ||
| MX2013007059A (es) | Emulsion de agua en aceite baja en grasa que contiene cantidades sustanciales de trigliceridos hoh. | |
| JP2016512693A5 (https=) | ||
| JP2013509378A5 (https=) | ||
| RU2017123761A (ru) | Предотвращение и лечение воспалительных состояний | |
| JP2012522826A5 (https=) | ||
| HRP20130985T1 (hr) | Protu-upalne djelatne tvari u euganejskom termalnom blatu | |
| JP2017535582A5 (https=) | ||
| JP2011012258A5 (https=) |